Ÿnsect and AgriProtein: When Insect Factories Go Bankrupt

Insect protein is one of the most promising ideas in the green transition. Black soldier fly larvae consume organic waste, reducing its mass by 39-80%, and convert it into a dried meal containing 40-50% crude protein and 20-35% crude lipid. The larvae are self-replicating bioconversion units. No bioreactors, no cell culture, no sterile rooms. The biology is 3.8 billion years old and works at ambient temperature.

The market logic was equally compelling. Global aquafeed costs represent roughly 70% of salmon farming operating costs, and fishmeal prices had risen 80% over the prior decade due to supply constraints in wild-catch fisheries. Insect meal is a direct substitute. The protein profile matches. The amino acid composition fits. The regulatory pathway was clearing: the EU approved insect protein in aquafeed in July 2017, and extended approval to poultry and swine feed in September 2021.

Investors agreed. Between 2017 and 2023, the insect protein sector attracted over $1.67 billion in cumulative public funding commitments, plus hundreds of millions more in private venture capital. Ÿnsect alone raised over $450 million. The projected global market for insect protein was forecast to reach $3.3 billion by 2030. The thesis was clear: waste-fed insects produce cheap, sustainable protein for animal feed. Scale up. Win.

Three of the sector's most prominent companies did not survive to see that market materialize. Their failures do not disprove the thesis. They reveal the specific ways that capital structure, regulatory timing, and facility scale can kill a company whose underlying biology works perfectly.

Three companies concentrated the sector's most visible failures. Each followed a different path to the same outcome: building production capacity ahead of the market that was supposed to absorb it.

Ÿnsect was the most heavily funded insect protein company in history. The French company raised over $450 million to build the world's largest vertical mealworm farm in Amiens, a 40,000 m² facility designed to produce 100,000 tonnes of mealworm products per year. Ÿnsect chose Tenebrio molitor (the yellow mealworm) rather than the more industrially common black soldier fly. Mealworms have a slower bioconversion cycle, narrower feedstock tolerance, and require feed-grade substrates, which eliminated access to the cheapest organic waste streams. The Amiens mega-facility faced construction delays and cost overruns. By 2024, it had not reached designed capacity, and the company entered judicial reorganisation.

AgriProtein was a South African BSF company that ceased operations around 2019, reporting $38.9 million in losses in its final year. AgriProtein built production capacity during a period when EU regulations had not yet approved insect protein for poultry and swine feed. That approval came in September 2021, two years after AgriProtein was already gone. The company accessed only private capital, burning through it while waiting for the downstream market to materialise. High fixed costs with variable demand realisation is the shared failure mode. Facilities that cannot reach designed utilisation rates generate losses regardless of the underlying biological efficiency.

Enterra Feed Corporation operated a BSF facility in Rocky View County, Alberta, processing 130 tonnes of pre-consumer food waste per day and producing approximately 10 tonnes of insect-based feed ingredients daily plus 10-15 tonnes of organic fertiliser. Enterra entered receivership in 2022. The timing was brutal: $523 million in new public funding for the insect protein sector was announced in 2023, one year after Enterra stopped operating. The receivership reflected financial structure and market timing failures, not process failure. The phrase "halted independent operations" in the filings suggests possible acquisition or restructuring rather than full liquidation.

Every insect protein pitch deck contains the same set of biological truths. All are real. And all are insufficient to overcome the economic gap between production cost and commodity pricing.

The protein overcounting problem deserves attention. The standard nitrogen-to-protein conversion factor (Kp) of 6.25, used across the industry, overestimates insect protein content by 21-32%. The empirically derived Kp for BSF larvae is approximately 4.62. This means the "40-50% crude protein" on every pitch deck is actually closer to 30-40% true protein. The discrepancy does not make insect protein unviable, but it means the value proposition per tonne of dried meal is lower than the numbers investors saw.

The yield arithmetic is similarly sobering. BSF larvae achieve an input-to-larval biomass conversion of 20-25%, but the final dried meal yield is approximately 7% of raw waste input. A facility processing 130 tonnes of waste per day, like Enterra's Rocky View plant, produces roughly 9-10 tonnes of insect meal. The tipping fee revenue from waste processing helps, but the product revenue side must command a 2.5-3x premium over soy to cover production costs. At current soy concentrate prices of €1,000-1,500 per tonne, the insect meal needs to sell above €3,500 per tonne. Fishmeal at €1,600-2,000 per tonne sits in a more favourable comparison, but the premium is still significant.

The Dutch baseline cost model for BSF production, the most granular public dataset available, breaks down the production cost of €5,116 per tonne of dry matter into three layers. Each layer contains a lesson about why the first movers failed.

The dominant cost line is raw substrate delivery at 37.9%. This is where regulation becomes an economic weapon. EU Regulation 2017/893 restricts insect farming to feed-grade substrates, excluding mixed food waste. Mixed food waste is the cheapest and most abundant feedstock. The restriction forces operators to source more expensive feed-grade materials, inflating the single largest cost line. In jurisdictions with more permissive substrate rules (parts of Asia, some US states), this line drops significantly.

Building and inventory at 28.5% reveals the fixed-cost trap that killed AgriProtein and Enterra. These are largely fixed costs: the facility exists whether it runs at 30% or 95% utilisation. A mega-facility designed for 100,000 tonnes per year but operating at 20,000 tonnes per year has the same mortgage, the same depreciation, and nearly the same maintenance. The cost per tonne at 20% utilisation is roughly five times the cost at full capacity. Both AgriProtein and Enterra ran well below designed capacity.

Ÿnsect compounded this problem by choosing mealworms over BSF. Mealworms require feed-grade grain substrates (not waste), have slower growth cycles, and produce lower yields per unit of input. The substrate cost line for mealworms is structurally higher than for BSF, because the feedstock itself costs more. This was a species selection error that no amount of capital could overcome.

Five criteria separate the companies that failed from the companies that survived. Not one of these criteria is biological. All of them are structural, financial, or strategic.

The pattern is stark. Every surviving company chose BSF over mealworms. Every surviving company phased its capacity expansion to match contracted demand rather than projected market size. Every surviving company locked in feedstock supply before building the facility that would consume it. InnovaFeed's co-location with ADM's corn processing plant in Decatur, Illinois is the clearest example: BSF larvae consume ADM's corn processing byproducts. The feedstock arrives via conveyor, not truck. Input costs drop. Waste disposal costs for ADM drop. Industrial symbiosis in practice.

AgriProtein failed four of five criteria. Ÿnsect failed three. Enterra was borderline on most criteria, which is reflected in its ambiguous outcome (receivership with possible restructuring rather than outright liquidation). The surviving companies passed four or five criteria. The correlation between viability score and survival is nearly perfect.

The three companies that survived and continue to operate share a set of strategic decisions that the failed companies did not make. None of these decisions are about biology. All of them are about market entry, capital structure, and feedstock economics.

Protix raised €45 million in 2017 from Aqua-Spark, Rabobank, and regional investors. It targeted aquafeed as a beachhead: a market where aquaculture feed costs dominate operating expenses and fishmeal supply is structurally constrained. Protix did not build a 100,000-tonne mega-facility. It built a 15,000 t/year plant in Bergen op Zoom, operated it, proved the economics, and only then secured a €37 million EIB loan for expansion into Poland. Phased capacity tied to proven demand.

InnovaFeed co-located its Decatur, Illinois facility directly with ADM's corn processing infrastructure. This is industrial symbiosis: BSF larvae consume corn processing byproducts via conveyor. InnovaFeed gets cheap, reliable feedstock. ADM reduces waste disposal costs. The feedstock cost line, the dominant expense at 37.9% of production cost, drops dramatically when the substrate arrives for free from next door. InnovaFeed's target is 60,000 t/year of insect protein, 20,000 t/year of insect oil, and 400,000 t/year of frass fertiliser. It is a B2B play targeting animal feed manufacturers, bypassing consumer acceptance barriers entirely.

EnviroFlight led the US regulatory pathway, securing AAFCO T60.117 definition approval for BSF larvae in salmonid feed, later extended to poultry. At roughly 3,200 t/year of dried BSFL, EnviroFlight is the smallest survivor. But it is profitable at that scale because it matched capacity to contracted demand and did not build ahead of its customer base.

The combined lesson: the insect protein model works when operators build incrementally, lock in feedstock supply before breaking ground, and enter via animal feed markets with established demand. It fails when operators build mega-facilities on projected market growth, access only private capital with venture-timeline return expectations, and choose species or substrates that inflate production costs.

Insect protein is not the next vertical farming. The comparison is tempting but misleading. Vertical farming fights physics: replacing free sunlight with purchased electricity for commodity produce. Insect protein works with biology: using self-replicating organisms to convert waste into high-value protein at ambient temperature. The fundamental economics are different.

The failures in the insect protein sector are capital structure failures, not technology failures. AgriProtein ran out of money waiting for a market that arrived two years later. Enterra entered receivership one year before a $523 million public funding wave that could have sustained it. Ÿnsect chose the wrong insect species and built too large too fast. None of them disproved the thesis. All of them proved that the thesis requires patient capital, phased construction, locked feedstock, and species selection grounded in industrial economics rather than marketing narratives.

The market's structural undersupply gap tells the forward story. Projected capacity by 2030 is 221,000 tonnes per year. Projected demand is 500,000 tonnes per year. The gap is 280,000 tonnes. The survivors, Protix, InnovaFeed, and EnviroFlight, are positioned to fill portions of that gap with proven unit economics. New entrants with access to the $1.67 billion in public commitments have a capital advantage that AgriProtein and Enterra never had.

BSF frass, the organic fertiliser byproduct, adds a revenue dimension that most financial models undervalue. Field trials in Madagascar showed +38% maize yield over commercial organic fertiliser, with 23% higher nitrogen uptake. The frass market is emerging, and it converts what was a waste disposal cost into a third revenue stream alongside protein and oil. InnovaFeed's model, producing 400,000 t/year of frass alongside its protein and oil, reflects this correctly.

The insect protein industry is not dead. It is entering its second act. The first act was venture-funded mega-builds ahead of market demand. The second act is phased, industrially embedded, publicly backed expansion into confirmed demand. The biology was never the problem. The capital structure was. That is the kind of failure the green transition can fix, because the economics improve with scale, regulation, and time. The convergence of insects, biochar, and soil carbon remains one of the most promising circular economy loops in the transition. It just needed the first movers to fall so the second movers could learn where the floor was.